
Opinion|Videos|February 8, 2024
BRCAAway: Novel Hormonal Therapies With PARP inhibitors in mCRPC
Tian Zhang, MD, and the Oncology Brothers discuss the BRCAAway trial, which is investigating abiraterone, olaparib, or the combination in patients with metastatic castration-resistant prostate cancer.






































